Aktiesnakken — Juni 2011
-
bdurph, cancer forskning er noget langvarigt stads
-
du skal nok have dit hoved undersøgt, men det er sikkert det klogeste lige nu
-
men - what else is new
-
biotek, og små turnaround cases bør iøvrigt kun fylde en meget lille del af ens samlede portefølje
-
så egentligt burde disse udsving bare interesserer en, istedet for at fortvivle
-
hvorfor er Genmab gået fra 54 til 42 uden nyhed?
-
Zalu måske?
-
træthed?
-
masser af interessante investorspørgsmål i det
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind